Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Section 3 of 6

Product information and disease description

394 evidence topics · 160 sources

Product description

Phase of product development

Launch

No evidence found.

Commercial launch preparation
FDA orphan drug designation, November 2023
FieldQuoted record
Generic name“varegacestat”
Date designated“11/02/2023”
Orphan designation“Treatment of desmoid tumors”
Orphan designation status“Designated”
FDA orphan approval status“Not FDA Approved for Orphan Indication”
Sponsor“Immunome, Inc.”
Development history: acquisition by Immunome from Ayala Pharmaceuticals, March 2024

Product information

Generic, brand name and therapeutic class of product
Brand name

No evidence found.

Dosage forms and strengths
Commercial dosage form and unit strengths

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Wnt/β-catenin and Notch pathway cross-talk in desmoid tumors
Pharmacodynamics
Exposure-response for safety in a pooled phase 1 to phase 3 population
Adverse event of interestIncidence, n (%)
Treatment-emergent serious adverse events“49 (31.2)”
Grade 2+ hypophosphatemia“47 (29.9)”
Grade 2+ fatigue“43 (27.4)”
Grade 2+ nausea/vomiting“31 (19.7)”
Grade 2+ diarrhea“59 (37.6)”
Ovarian toxicity“32 (50.0)”
Grade 2+ rash“58 (36.9)”
Grade 2+ ALT elevation“9 (5.7)”
Note“Safety analysis population count was (N = 157) for all endpoints except ovarian toxicity (N = 64).”
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Hepatic impairment: single-dose pharmacokinetic study design

“This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.” (opens the source at this quote in a new tab)

“This is an open-label, single-dose, parallel study to evaluate the effects of varying degrees of impaired hepatic function on the PK, safety, and tolerability of varegacestat in adult participants.” (opens the source at this quote in a new tab)

“The study will enroll participants with mild (Group 2) and moderate (Group 3) hepatic impairment (HI) and healthy participants with normal hepatic function (Group 1) at a 1:1 ratio.” (opens the source at this quote in a new tab)

“Subsequently, if appropriate, the study will enroll participants with severe (Group 4) HI and healthy participants with normal hepatic function (Group 1), as needed, to provide 1:1 matches for Group 4. The decision to conduct Group 4 enrollment will be contingent upon the assessment of the feasibility, PK, and safety data from Groups 1-3.” (opens the source at this quote in a new tab)

“Has a score on the Child-Pugh scale at screening visit and confirmed at check-in as follows:” (opens the source at this quote in a new tab)

“Mild: ≥5 and ≤6 [Category A]; or” (opens the source at this quote in a new tab)

“Moderate: ≥7 and ≤9 [Category B]; or” (opens the source at this quote in a new tab)

“Severe: ≥10 and ≤15 [Category C].” (opens the source at this quote in a new tab)

Ovarian toxicity in premenopausal women
Drug/Drug, drug/disease interactions
Effects of other drugs on Varegacestat
Effects of Varegacestat on other drugs
Dosing and administration
Dosage
Administration
Access and distribution
Specialty pharmacy or specialty distributor arrangements

No evidence found.

Co-prescribed/Concomitant therapies
Effect of Varegacestat on quality measures

No evidence found.

Product comparison

Place of product in therapy

Disease description

Definition and etiology
Desmoid risk after risk-reducing colectomy in familial adenomatous polyposis by APC genotype and family history
Epidemiology
Incidence of Desmoid tumors
Prevalence of Desmoid tumors
Natural history, survival, and mortality
Active surveillance: pooled analysis of three prospective observational studies, extra-abdominal desmoid-type fibromatosis
Pathophysiology
Notch pathway cross-talk and overexpression

“Cross-talk between the Notch and Wnt pathways, as well as activation of the Notch pathway resulting from dysregulation of the Wnt pathway, suggest a possible therapeutic target for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Subsequent studies analyzed the expression of Notch pathway components in DT tissues and cell strains, and confirmed increased expression of HES1 in DT versus dermal scar tissue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Dysregulation of the Wnt signaling pathway plays a key role in DT pathogenesis, however, as the result of crosstalk, Wnt dysregulation may lead to activation of the Notch pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The overexpression of Notch pathway components in DT provides a rationale for development of pharmacologic agents targeting Notch.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Due to the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain (with subsequent translocation to the nucleus to activate gene transcription), γ-secretase inhibitors (GSIs) have emerged as a potential treatment for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Diagnosis
Imaging: magnetic resonance imaging for diagnosis, local staging, and follow-up
Clinical presentation - signs and symptoms
Physical function: decreased range of motion and loss of mobility
Symptom elicited in concept elicitation interviews (n = 31)Frequency of mentionsMedian disturbance rating
Decreased range of motion“21”View highlighted excerpt for this quote“4.00”View highlighted excerpt for this quote
Stiffness“10”View highlighted excerpt for this quote“3.00”View highlighted excerpt for this quote
Appearance: disfigurement and swelling
Symptom elicited in concept elicitation interviews (n = 31)Frequency of mentionsMedian disturbance rating
Disfigurement/altered appearance“25”View highlighted excerpt for this quote“5.00”View highlighted excerpt for this quote
Swelling“6”View highlighted excerpt for this quote“5.00”View highlighted excerpt for this quote
Long-term morbidity
Long-term use of analgesics and other medications
Burden of Desmoid tumors
Humanistic burden and health-related quality of life
Desmoid Tumor Research Foundation natural history study, 2017 to 2023

“Surveys were completed by 399 participants between September 2017 and August 2023. The median age of participants was 38 years; most were female (72%, 288/399), White (84%, 334/399), or resided in North America (86%, 345/399).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants with the presence of DT at survey completion reported significantly worse scores for pain, extra-abdominal symptoms, fatigue, physical functioning, and sleep in comparison to those without the current presence of a DT (P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The overall mean Total Symptom Score for all participants was 4.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The symptoms and impact of DT in a joint/extremity were reported to be significantly worse for the DTSS Total Symptom Score, DTSS Pain domain, and the DTIS Physical Functioning domain compared with other DT locations (all P < 0.05; Fig. 7a-c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Conversely, regardless of the current presence of DT, participants reported similar mean scores (P > 0.05) for the DTIS Emotional Impact domain (4.4 with current DT vs. 3.9 without current DT) and all Emotional Impact domain item scores, including Fear of Desmoid Tumor Growth/Recurrence (5.8 vs. 5.2), Anger (3.4 vs. 3.1), Anxiety (4.5 vs. 4.0), and Frustration (4.8 vs. 4.0), except Hopelessness (3.7 vs. 2.7; P = 0.007; data not shown).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Health state utility values in the NICE appraisal of nirogacestat

“Although the De‑Fi trial did not collect EQ-5D data, it did collect quality-of-life data using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30.” (opens the source at this quote in a new tab)

“The utility values in the company base case were instead informed by published utility values from people with soft-tissue sarcoma (Shingler et al. 2013).” (opens the source at this quote in a new tab)

“The EAG stated that the utility value for progressed disease in the company base case was implausibly low for people with desmoid tumours (0.263).” (opens the source at this quote in a new tab)

“But, because this data was not provided, the EAG preferred to use utility values based on EQ-5D data from a clinical trial of people with soft-tissue sarcoma (Reichardt et al. 2012). This resulted in a utility value of 0.560 for progressed disease.” (opens the source at this quote in a new tab)

“The company acknowledged that the true utility value of progressed disease was likely to be between the company (0.263) and the EAG (0.560) base cases.” (opens the source at this quote in a new tab)

“At the second committee meeting, the company presented the EORTC QLQ-C30 quality-of-life data from De‑Fi, mapped to EQ-5D using the method from Young et al. (2015). These utilities are considered confidential by the company and so cannot be reported here.” (opens the source at this quote in a new tab)

Economic burden and healthcare resource utilization
United States academic center resource utilization, 2011 to 2023
Economic impact of Desmoid tumors on families
Family-related impacts reported in GODDESS concept elicitation interviews
Economic impact of diagnostic testing
Cost of centralized histological review in the French RRePS network

“A decision tree was used to assess the expected costs of two strategies of disease management: one based on revised diagnoses after centralized histological review (option 1), the other on diagnoses without centralized review (option 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The time horizon was 12 months and the perspective of the French National Health Insurance (NHI) was retained. Costs were expressed in Euros for 2013.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 2,425 patients were included. Three hundred forty-one patients (14%) had received discordant diagnoses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The probability of discordance was higher for a final diagnosis of desmoid tumors when compared to liposarcomas (odds ratio = 5.1; 95%CI [2.6–10.4]). The expected costs per patient for the base-case analysis (low- and high-case scenarios) amounted to €8,791 (€7,033 and €10,549, respectively) for option 1 and €8,904 (€7,057 and €10,750, respectively) for option 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Centralized histological reviews are likely to provide cost-savings for the French NHI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Concordance and 12-month management cost by initial and final diagnosis involving desmoid tumors

Approaches to treatment

Current treatment options and standard of care
Active surveillance
Pooled analysis of three prospective observational studies: treatment-free survival and progression

“In this pooled analysis from three prospective observational studies on patients with extra-abdominal desmoid-type fibromatosis, we confirm that spontaneous regression occurs in a significant proportion of patients and that two-thirds are treatment free at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients (n = 282) with a median follow-up of 53 months (IQR, 39–63) were included. The 3- and 5-year TFS rates were 67% and 66%, respectively; the 3- and 5-year crude cumulative incidences were 33% and 34% for RECIST progression, 26% and 34% for RECIST regression, and 33% and 38% for regression post-RECIST progression, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The 3- and 5-year PFS rates (95% CI) were 54% (48%–60%) and 51% (45%–58%), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In total, 93 of 282 (33.0%) patients received AT after initial AS, of which 45 (48.4%) patients received AT after RECIST progression, and 48 (54.6%) patients received AT after symptomatic progression alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

GRAFITI prospective cohort study of non-intraabdominal tumors

“In this multicenter prospective cohort study (NTR4714), adult patients with non-intraabdominal DTF were followed during an initial AS approach for 3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 105 patients started with AS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At 3 years, cumulative incidence of the start of active treatment was 30% (95% confidence interval [CI] 21–39) and PFS was 58% (95% CI 49–69). Median time to start active treatment and PFS were not reached at a median follow-up of 33.7 months. During AS, 32% of patients had stable disease, 28% regressed, and 40% demonstrated initial progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Larger tumor size (≥5 cm; hazard ratio = 2.38 [95% CI 1.15–4.90]) and S45F mutation (hazard ratio = 6.24 [95% CI 1.92–20.30]) were associated with the start of active treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The follow-up protocol of the GRAFITI trial consisted of follow-up visits and imaging examinations (Ultrasound [US] and MRI) at baseline, 3,6,9,12,18,24, and 36 months (window ±3 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Surgery
Radiotherapy
EORTC 62991-22998 multicenter prospective phase II trial: local control and response

“To determine the activity of radiotherapy in patients with inoperable desmoid-type fibromatosis (DF) a multicenter prospective phase II trial was carried out.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“(EORTC 62991-22998)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients with inoperable progressive disease of primary, recurrent or incompletely resected lesions received a dose of 56 Gy in 28 fractions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Forty-four patients (27 F/17 M) were enrolled from 2001 to 2008. Median age was 39.5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Median follow-up was 4.8 years. The 3-year local control rate was 81.5% (90% one-sided confidence interval 74% to 100%). Best overall response during the first 3 years was complete response (CR) 6 (13.6%), partial response (PR) 16 (36.4%), stable disease 18 (40.9%), progressive disease 3 (6.8%) and nonassessable 1 (2.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Response after radiation therapy is slow with continuing regression seen even after 3 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Cryoablation and other local ablative therapies
Gamma secretase inhibitors
DeFi long-term follow-up through December 2024

“Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of the 70 patients randomly assigned to nirogacestat in the DB phase, 39 continued in the OLE” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, 33 and 15 patients received nirogacestat for at least 3 and 4 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No additional events (progression or death) occurred with additional exposure after year 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The ORR was 34.3%, 41.4%, 44.3%, and 45.7% in patients who received nirogacestat for up to 1, 2, 3, and 4 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Optimal duration of treatment and the presence and frequency of additional tumor responses after treatment discontinuation are not well defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Real-world nirogacestat use in the French compassionate use program (DeNi study)
Tyrosine kinase inhibitors
Sorafenib phase 3 trial: design and efficacy

“In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001). Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median time to an objective response among patients who had a response was 9.6 months (interquartile range, 6.6 to 16.7) in the sorafenib group and 13.3 months (interquartile range, 11.2 to 31.1) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“On the basis of the predictable toxic-effects profile and substantial progression-free survival advantage conferred by sorafenib, the drug has antitumor activity as first-line therapy or as subsequent therapy for desmoid tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Chemotherapy
Pegylated liposomal doxorubicin in a placebo-controlled phase 3 trial

“In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Seven (14.9%) patients experienced grade 3 or 4 AEs in the PLD group, including neutrophil count decreased (10.6%), mucositis oral (6.4%), white cell decreased (4.3%), and palmar–plantar erythrodysesthesia syndrome (2.1%). No patients reported cardiotoxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“First, the interpretation of our results is limited by a single-center design and relatively small sample size, which had the potential to introduce bias, although these aspects are consistent with other phase III trials in this rare disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Lastly, the current follow-up period may not be sufficient to adequately assess the cardiotoxicity associated with low cumulative doses of PLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Nonsteroidal anti-inflammatory drugs and hormonal therapy
Limitations of current therapies
Summary: limitations of active surveillance and local therapies
  • Active surveillance: in a pooled analysis of 282 participants, 93 (33.0%) received active treatment after initial surveillance, and the 5-year crude cumulative incidence of RECIST progression was 34%. In a United Kingdom cohort of 168 participants, 46% proceeded to treatment, for pain (32%), progression (31%), or both (13%). Guidelines call for a first MRI within 1-2 months and then imaging at 3-6 month intervals, and surveillance may not be appropriate if progression could “be life-threatening or pose a risk for mutilation”.
  • Surgery: NCCN and Desmoid Tumor Working Group guidelines “no longer support surgery as the first-line option in most situations” because of high postsurgical recurrence rates. Reported postsurgical recurrence reaches 50% to 88%, and 30%-90% for extremity tumors; after complete gross resection, 23% of patients had recurrence. In unfavorable locations, 2-year event-free survival was 25% after initial surgery and 52% with wait-and-see. Amputation was reported by 7% (12/163) of survey participants who had surgery, and 83% of them reported regrowth or recurrence afterward.
  • Radiotherapy: in the EORTC 62991-22998 phase II trial (44 participants), the 3-year local control rate was 81.5% and response was slow. A review of 317 participants treated with definitive radiation reported local control in 79.8%, frequent late fibrosis, contracture, joint stiffness, skin disorders, lymphedema, and pain, and 6 secondary malignancies in the radiation field. The evidence for adjuvant radiotherapy is low, and it carries a risk of radiation-induced sarcoma “in this young patient population”.
  • Ablation: in CRYODESMO-01 (50 participants), the 12-month non-progression rate was 86%, and grade 3-4 toxicity occurred in 22%. A systematic review of 146 participants reported major complications in 13.3-30%, and across 694 lesions treated with cryoablation, HIFU, or microwave ablation, severe nerve injury was the most common major complication (26.3%). Cryoablation is of limited use for larger tumors involving vital structures, and ablative approaches are not available in every center and require particular expertise.
Summary: limitations of systemic therapies
  • Comparative evidence: the Desmoid Tumor Working Group stated that “due to the lack of comparative studies” no definitive sequence of systemic treatments could be proposed, with randomized data then existing for sorafenib, pazopanib, and methotrexate plus vinblastine. The NCCN guidelines (version 1.2025, as restated in a Cigna policy) list nirogacestat and sorafenib as category 1 and the other listed agents as category 2A.
  • Gamma secretase inhibitors: in DeFi, dose reductions due to adverse events occurred in 42% of nirogacestat recipients (0% with placebo) and discontinuation due to adverse events in 20% (1% with placebo); ovarian dysfunction occurred in 27 of 36 women of childbearing potential (75%), with resolution reported in 78% (21 of 27) as of October 24, 2022, including all 11 who stopped treatment. The label carries warnings for diarrhea, ovarian toxicity, hepatotoxicity, non-melanoma skin cancers, electrolyte abnormalities, hypersensitivity reactions (added in August 2026), and embryo-fetal toxicity, and advises avoiding strong or moderate CYP3A inhibitors and inducers and gastric acid reducing agents. The appropriate treatment duration is unknown, and nirogacestat is “still not widely available outside of the United States”.
  • Tyrosine kinase inhibitors are used off label and are not commissioned in the NHS in England for desmoid tumours. In the sorafenib phase 3 trial, adverse events led to discontinuation in 20% (no placebo patients), dose reductions due to toxic effects occurred in 31% vs 11%, and grade 1 or 2 rash occurred in 73%. In an 11-institution cohort of 142 participants treated with sorafenib or pazopanib, 59.9% discontinued treatment, mainly for toxicity. Imatinib trials showed response rates of 6–19%, and in DESMOPAZ grade 3 or 4 hypertension occurred in 21% of the pazopanib group.
  • Chemotherapy is “not licensed for treating desmoid tumours” (NICE). Response rates are in the range of 35–40% and usually occur several months after the start of therapy. In DESMOPAZ, 45.0% of the methotrexate-vinblastine group had not progressed at 6 months, and neutropenia occurred in 45%. Systematic reviews reported grade 3 or 4 adverse event rates of 31% for low-dose methotrexate plus vinblastine and 28% for doxorubicin-based regimens, and grade 3 events were more frequent with anthracycline regimens than with sorafenib (27% vs 14%). NICE judged the hazard ratio of 0.05 for chemotherapy versus placebo in Xu et al. “implausibly large”, and experts stated that pegylated liposomal doxorubicin is not used for desmoid tumours in the UK.
  • Hormonal therapy and NSAIDs: the Desmoid Tumor Working Group found “no evidence to consider antihormonal therapies and NSAIDs”, and hormone antagonists are no longer recommended in its consensus guidelines; NCCN lists sulindac or other NSAIDs for pain as useful in certain circumstances (category 2A). In a Children's Oncology Group phase II study of tamoxifen plus sulindac, responses occurred in 8% (5/59), 2-year PFS was 36%, and 12 of 30 females (40%) developed ovarian cysts. Toremifene 60 mg daily was ineffective (12-month PFS 4.8%), and the S45F mutation was associated with poor response to meloxicam.
Place in treatment, anticipated use, and care setting
Summary
  • The NDA under FDA review proposes varegacestat “for the treatment of adults with desmoid tumors”.
  • The Desmoid Tumor Working Group considers active surveillance the first step after diagnosis in the majority of patients and proposes active treatment only in case of persistent progression. Treatment choice is guided by anatomical site: surgery remains the first option at progression for abdominal wall tumors, systemic therapy is the first option for intra-abdominal, retroperitoneal, and pelvic tumors, and medical therapy is preferred for extremity, girdle, and chest wall tumors and is first line for head and neck and intrathoracic tumors. The group states that no definitive sequence of systemic treatments can be proposed because comparative studies are lacking.
  • The 2023 global consensus update addressed the positioning of gamma secretase inhibitors, with nirogacestat the first approved drug for desmoid tumors. NCCN soft tissue sarcoma guidelines version 1.2025, as quoted in a Cigna coverage policy, list Ogsiveo and sorafenib as category 1 and methotrexate-based, imatinib, pazopanib, and doxorubicin-based regimens as category 2A.
  • The approved gamma secretase inhibitor, OGSIVEO (nirogacestat), is indicated for adult patients with progressing desmoid tumors who require systemic treatment, at 150 mg orally twice daily until disease progression or unacceptable toxicity. NICE recommends nirogacestat within its marketing authorisation; in its appraisal, current options in England are off-label chemotherapy, off-label tyrosine kinase inhibitors, and surgery, and nirogacestat is expected to displace chemotherapy and best supportive care.
  • RINGSIDE Part B enrolled 156 participants with progressive disease (tumor growth of at least 20% within the past 12 months) who were either treatment-naïve with tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.
  • Immunome states that systemic therapy is recommended for about 75% of tumors after progression during initial active surveillance, that gamma secretase inhibitors “may ultimately capture much of the market for desmoid tumor therapy”, and that it aims to “Become Standard of Care treatment of Desmoid Tumors”. It describes varegacestat as oral and once daily, estimates “10-11k Actively Managed Patients (US)”, and anticipates that patients may receive about 1.5 to 2 years of treatment, pause, and return for treatment.
  • Immunome plans to commercialize in the United States through a targeted sales force designed to reach specialized treatment centers, and its corporate presentation names about 85 sarcoma centers of excellence.
Heterogeneity of treatment effect
RINGSIDE Part B progression-free survival across subgroups
Care management intervention strategies
Management in designated referral centers with a multidisciplinary tumor board
Ovarian toxicity monitoring and fertility counseling
Onset of adverse events with varegacestat in RINGSIDE Part B
Adverse event (varegacestat, N=79)All grades, n (%)Median time to onset (days)
Diarrhea“65 (82.3)”“14.0”
Nausea“28 (35.4)”“8.0”
Rash“56 (70.9)”“24.0”
Fatigue“46 (58.2)”“27.5”
Hypophosphatemia“27 (34.2)”“29.0”
Ovarian toxicity“20 (25.3)”“56.5”
Commercial payer prior authorization criteria for nirogacestat
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Summary
  • Treatment of progressing desmoid tumors aims to control tumor growth and relieve symptoms. NICE describes it as “non-curative and aims to control tumour growth and alleviate symptoms”, the 2023 consensus update calls for selecting each patient's management strategy to optimize tumor control and enhance quality of life, and Immunome states that treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function.
  • Tumor control with varegacestat in RINGSIDE Part B (data cutoff October 7, 2025): PFS of 94% at 1 year and 89% at 2 years with varegacestat, compared with 66% and 57% with placebo; a hazard ratio of 0.16 (95% CI 0.071, 0.375) and a confirmed objective response rate of 56% versus 9% in Immunome's ESMO release; and a median time to response of 8.2 months among varegacestat responders.
  • Symptom outcomes in RINGSIDE Part B: Immunome reports a worst pain difference of more than 2 points from the first evaluation at week 4. At week 48, least-squares mean changes were -1.50 with varegacestat and +0.59 with placebo on the GODDESS TSS-5 symptom score, and +3.90 and -3.04 on PROMIS Physical Function.
  • Treatment duration: median exposure in RINGSIDE Part B was 20.3 months with varegacestat as of October 7, 2025, and median time on treatment in RINGSIDE phase 2 as of April 10, 2024 was 23.1 months in one abstract and 25.4 months in another. Immunome anticipates that patients may receive about 1.5 to 2 years of treatment, pause, and return for treatment.
  • Pauses and retreatment: in the NICE appraisal of nirogacestat, clinical experts supported stopping after 2 years if treatment could continue while the tumor was still shrinking or restart if it grew again. The company reported that less than 1% of people in its compassionate use programme continued beyond year 2, and the committee assumed that most patients stop after 2 years. The long-term nirogacestat follow-up publication (Ratan et al. 2025) states that optimal duration and responses after discontinuation are not well defined. The Desmoid Tumor Working Group states that shrinkage can continue after withdrawal, that long-term disease control is achieved in up to 50–70% of patients, and that treatment can be repeated at recurrence.
  • Long-term continuous nirogacestat: in long-term follow-up of participants randomly assigned to nirogacestat, the objective response rate was 34.3%, 41.4%, 44.3%, and 45.7% with up to 1, 2, 3, and 4 years of treatment, with no additional progression or death events after year 2. In the French DeNi real-world study, median treatment duration was 16 months, the 1-year PFS rate was 76.2%, and 38 of 49 participants with baseline pain (78%) reported pain improvement.
Treatment duration, pauses, and retreatment with gamma secretase inhibitors

“The EAG noted that clinical experts broadly supported stopping treatment after 2 years. But it added that this was only if there was flexibility to continue for longer if the tumour was still shrinking, or restart if, for example, the tumour started growing again.” (opens the source at this quote in a new tab)

“The company provided data on tumour size plateaus. It said that by year 2, 100% of tumours had plateaued in people with complete and partial response. In people with stable disease, more than 75% of tumours had plateaued.” (opens the source at this quote in a new tab)

“It recalled that retreatment with nirogacestat was not permitted in De-Fi, so the trial did not provide evidence on restarting treatment after stopping.” (opens the source at this quote in a new tab)

“The company highlighted that based on data from its compassionate use programme (up to April 2025), less than 1% of people having nirogacestat continue treatment beyond year 2.” (opens the source at this quote in a new tab)

“They explained that people in their practice usually stop nirogacestat after about 1 year, very few would continue beyond year 2 and the number of people needing retreatment is low.” (opens the source at this quote in a new tab)

“So, the committee concluded that while it would not recommend a stopping rule, the model should assume that most patients stop treatment after 2 years to align with clinical practice, with a proportion of people continuing or restarting treatment.” (opens the source at this quote in a new tab)